
    
      Subjects are patients with glioblastoma (GBM), anaplastic astrocytoma (AA) or grade 3 or
      greater WHO astrocytic, oligodendroglial or mixed glial tumors, which were initially
      diagnosed by histologic examination of biopsy/resection. Modified classical "3+3" phase I
      design used to determine maximum tolerated dose of topotecan in combination with Temodar.
    
  